KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other Non-Current Assets: 2011-2024

Historic Other Non-Current Assets for Alnylam Pharmaceuticals (ALNY) over the last 11 years, with Dec 2024 value amounting to $65.3 million.

  • Alnylam Pharmaceuticals' Other Non-Current Assets fell 28.06% to $55.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.8 million, marking a year-over-year decrease of 28.06%. This contributed to the annual value of $65.3 million for FY2024, which is 5.51% up from last year.
  • According to the latest figures from FY2024, Alnylam Pharmaceuticals' Other Non-Current Assets is $65.3 million, which was up 5.51% from $61.9 million recorded in FY2023.
  • Alnylam Pharmaceuticals' Other Non-Current Assets' 5-year high stood at $66.1 million during FY2022, with a 5-year trough of $45.0 million in FY2020.
  • For the 3-year period, Alnylam Pharmaceuticals' Other Non-Current Assets averaged around $64.4 million, with its median value being $65.3 million (2024).
  • In the last 5 years, Alnylam Pharmaceuticals' Other Non-Current Assets surged by 149.29% in 2020 and then dropped by 6.34% in 2023.
  • Yearly analysis of 5 years shows Alnylam Pharmaceuticals' Other Non-Current Assets stood at $45.0 million in 2020, then skyrocketed by 33.65% to $60.2 million in 2021, then grew by 9.78% to $66.1 million in 2022, then dropped by 6.34% to $61.9 million in 2023, then climbed by 5.51% to $65.3 million in 2024.